How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma

Annals of Oncology

Volumn 23, Issue SUPPL.8, 2012, Pages

  Wolchok, J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cytotoxic T lymphocyte associated antigen 4 (CTLA 4); Immune related adverse events (irAEs); Immunotherapy; Ipilimumab; Melanoma; Vemurafenib

Indexed keywords

CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; GLYCOPROTEIN GP 100; INFLIXIMAB; IPILIMUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; VEMURAFENIB;

ARTHRALGIA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; COLITIS; CONFERENCE PAPER; DIARRHEA; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; ENTEROCOLITIS; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIVER TOXICITY; MEDICAL DECISION MAKING; METASTATIC MELANOMA; MONOTHERAPY; OVERALL SURVIVAL; PATIENT CARE; PHARMACOLOGICAL BLOCKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN DISEASE; SKIN TUMOR; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; INDOLES; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF; STANDARD OF CARE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84865553349     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds258     Document Type: Conference Paper

References (28)

1. Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485-1492.
2. Garbe C, Eigentler TK, Keilholz U et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011; 16: 5-24.
3. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
4. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
5. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
6. Allison JP, Krummel MF. The Yin and Yang of T-cell costimulation. Science 1995; 270: 932-933.
7. Melero I, Hervas-Stubbs S, Glennie M et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7: 95-106.
8. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006; 90: 297-339.
9. Schneider H, Downey J, Smith A et al. Reversal of the TCR stop signal by CTLA- Science 2006; 313: 1972-1975.
10. Korman A, Yellin M, Keler T. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs 2005; 6: 582-591.
11. Peggs KS, Quezada SA, Korman AJ et al. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006; 18: 206-213.
12. Sharpe AH, Abbas AK. T-cell costimulation--biology, therapeutic potential, and challenges. N Engl J Med 2006; 355: 973-975.
13. O'Day SJ, Maio M, Chiarion-Sileni V et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21: 1712-1717.
14. Weber J, Thompson JA, Hamid O et al. A randomized, double-blind, placebocontrolled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15: 5591-5598.
15. Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155-164.
16. Agarwala SS. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Res 2010; 20: 1-10.
17. Hersh EM, O'Day SJ, Powderly J et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 2011; 29: 489-98.
18. Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12: 1005-1016.
19. Dancygier H, Runne U, Leuschner U et al. Dacarbazine (DTIC)-induced human liver damage light and electron-microscopic findings. Hepatogastroenterology 1983; 30: 93-95.
20. Frosch PJ, Czarnetzki BM, Macher E et al. Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma. J Cancer Res Clin Oncol 1979; 95: 281-286.
21. Greenstone MA, Dowd PM, Mikhailidis DP et al. Hepatic vascular lesions associated with dacarbazine treatment. Br Med J (Clin Res Ed) 1981; 282: 1744-1745.
22. YERVOY™ Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002213/WC500109299.pdf (July 2011, date of preparation).
23. Lin R, Yellin MJ, Lowy I et al. An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: prevention of gastrointestinal perforation and/or colectomy. J Clin Oncol 2008; 26(15 Suppl), Abstr 9063.
24. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007; 12: 864-872.
25. Wolchok JD, Hoos A, O'day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420.
26. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-2147.
27. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
28. Zelboraf™ Summary of Product Characteristics. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002409/human_med_001544.jsp&mid=WC0b01ac058001d124.pdf (March 2012, date of preparation).